Dave O'Neill – Managing Director – American West Metals (ASX:AW1) ) is an Australian clean energy mining company focused on growth through the discovery and development of major base metal mineral deposits in Tier 1 jurisdictions of North America.
Copyright 2024 – Finance News Network
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
06 Jul 2023 - Tamboran Resources Limited (ASX:TBN) Managing Director and CEO Joel Riddle discusses the company's recent capital raise, the drilling timeline, and agreements with APA Group, Clean Energy Fuels Australia, BP and Shell.
27 May 2021 - Next Science Limited (ASX:NXS) Founder and Chief Technology Officer Dr Matthew Myntti talks about the problem of biofilms, Next Science's antimicrobial treatments and the company's recent FDA approval.
06 Sep 2022 - Kinetiko Energy Limited (ASX:KKO) CEO Nick de Blocq discusses the South African energy market and the role of gas in the clean energy transition.
04 Sep 2023 - Glen Diemar, Managing Director of Australian Gold and Copper Limited (ASX:AGC), provides an update on the company, discussing drill targets, plans and outlook.
24 Mar 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses historical precedence for recovering from government spending, the possible rise of interest rates, labour market data, and investment strategies in this environment.
24 May 2021 - BluGlass Limited (ASX:BLG) Non-Executive Director Jean-Michel Pelaprat talks about joining BluGlass, his experience, and the future for BluGlass's gallium nitride technology.
16 Aug 2023 - Dr John Melki - CEO and Director - Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
25 Oct 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses efficacy results for the company's glioblastoma therapy.
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.